Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia (Q46604957)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 9 May 2008

Language	Label	Description	Also known as
English	Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia	scientific article published on 9 May 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Frank Schneider

13

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Joachim Klosterkötter

9

object named as

Joachim Klosterkötter

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Hans-Jürgen Möller

1

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

Gerhard Buchkremer

7

object named as

Gerhard Buchkremer

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

2

object named as

Michael Riedel

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Ralf G. Schlösser

12

object named as

Ralf Schlösser

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Christian Ohmann

14

object named as

Christian Ohmann

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

author name string

Markus Jäger

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Florian Wickelmaier

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Wolfgang Maier

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Kai-Uwe Kühn

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Isabella Heuser

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Markus Gastpar

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Dieter F Braus

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Mathias Riesbeck

15

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Wolfgang Gaebel

16

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

publication date

9 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

number of pages

13

1 reference

based on heuristic

inferred from page(s)

The International Journal of Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

985-997

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Statistics notes: Analysing controlled trials with baseline and follow up measurements

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

The Prognosis of Schizophrenia: Rationale for a Multidimensional Concept*

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Prognostic variables at intake and long-term level of function in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Intraclass correlations: uses in assessing rater reliability

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Olanzapine and haloperidol in first episode psychosis: two-year data

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Psychopathological and social outcome in schizophrenia versus affective/schizoaffective psychoses and prediction of poor outcome in schizophrenia. Results from a 5-8 year follow-up

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Medication adherence of individuals with a first episode of psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Clinical evaluation of negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Negative symptoms in schizophrenia. Definition and reliability

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Course and long-term treatment of schizophrenic psychoses

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Management of the negative symptoms of schizophrenia: new treatment options

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

A rating scale for mania: reliability, validity and sensitivity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

21 January 2018

Optimal haloperidol dosage in first-episode psychosis.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

German research network on schizophrenia-bridging the gap between research and care

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

Premorbid and onset features of first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G)

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

A depression rating scale for schizophrenics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

The serotonin paradox: Negative symptoms and SSRI augmentation

1 reference

https://api.crossref.org/works/10.1017%2FS1461145708008791

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S1461145708008791

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18466670

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46604957&oldid=2121708068"